Mirum Pharmaceuticals price target raised to $50 from $44 at Baird

Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $50 from $44 and keeps an Outperform rating on the shares. The firm said they reported a solid beat over expectations driven by Livmarli, leading them to raise FY2024 guidance above the top end of the previous range.